CA1331615C - Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids - Google Patents

Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids

Info

Publication number
CA1331615C
CA1331615C CA000616412A CA616412A CA1331615C CA 1331615 C CA1331615 C CA 1331615C CA 000616412 A CA000616412 A CA 000616412A CA 616412 A CA616412 A CA 616412A CA 1331615 C CA1331615 C CA 1331615C
Authority
CA
Canada
Prior art keywords
acid
tetrahydro
hydrochloride
amino
oxopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000616412A
Other languages
French (fr)
Inventor
Milton L. Hoefle
Sylvester Klutchko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parke Davis and Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26889329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1331615(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to CA000616412A priority Critical patent/CA1331615C/en
Application granted granted Critical
Publication of CA1331615C publication Critical patent/CA1331615C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ABSTRACT
The invention relates to substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid compounds having the formula

Description

I 331 ~ ~

This application is a division of copending Canadian Patent Application No. 387,002 filed September 30, 1981.

The invention relates to S, S, S, isomers of 5 substituted acyl derivatives of 1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid compounds having the f ormula COO~ . `
* I H 11 Ar ~CH2) m I E~ NE~ C* C
COOR 2 '~q ~X

( I ) ' ' JJ: *

~ . . . .... . . .. .. ..
2 ~L331Sl~
where R is hydrogen, lower alkyl or aralkyl; Rl is hydrogen, lower alkyl, or benzyl; R2 is hydrogen or lower alkyl, and Ar is phenyl or phenyl substituted with 1 or 2 substituents s~lected from the group consisting of fluorine, chlorine, bromine, lower alkyl, lower alkoxy, hydroxy or amino; X and Y are independently hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, hydroxy, or X and Y together are methylenedioxy; m is O to 3; and the pharmaceutically acceptable acid salts thereof.
Preferred compounds of the invention are acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids having the formula COOH
Rl O
I 11 ~
Ar-(CH2)2-CIH-NH-CH-C-N

~X

where R1 is hydrogen or lower alkyl containing 1 to 3 carbon atoms, R2 is hydrogen or lower alkyl containing 1 to 3 carbon atoms and Ar is phenyl, and phenyl substituted in the para position by fluorine, chlorine, bromine, methyl, hydroxy, methoxy or amino; and pharmaceutically acceptable acid salts thereof.

JJ:rn 133~

Further preferred compounds of the invention are acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids having the formula COOH

C~ -C~12-fH-NH-CH-C-N
COOR2 ~ q ~X

where R2 is hydrogen or lower alkyl containing 1 to 3 carbon atoms X and Y are independently hydrogen or lower alkoxy and pharmaceutically acceptable acid salts thereof; and specifically the compounds designated 2-t2-~(l-carboxy-3-phenylpropyl)amino]-l-oxopropyl]-l~2~3~4-tetrahydro-3-isoquinolinecarboxylic acid; 2-t2-t[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2~3~4-tetrahydro-3-isoquinolinecarboxylic acid; 2-t2-t(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic acid;
2-~2-[~1-(ethoxycarbonyl)-3-phenylpropyl]amino]-}-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid; and pharmaceutically acceptable acid salts thereof.
The terms "lower alkyl" and "lower alkoxy" are intended to mean a straight or branched alkyl group of from one to four carbon atoms.
The compounds of the invention of formula I have asymmetric carbon atoms indicated by asterisks. The 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid used in this invention has the L (S) configuration. This configuration has been shown to be required for biological activity, and thus active compounds of the invention are derived from JJ:rn ~33~6~ ~

either L(-) or D~-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Optical and diastereo isomers arising from the chirality at the centers marked with an asterisk in formula I ~nd racemates and mixtures thereof are within the scope of this invention. The S configuration at these centers i5 preferred.
The compounds of the invention may exist in anhydrous form as well as in solvated, including hydrated forms. In general, the hydrated forms and the solvated forms with pharmaceutically acceptable solvents are equivalent to the anhydrous or unsolvated form for the purposes of the invention.
The compounds of the invention of formula I may be prepared from 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid by first protecting the carboxylic acid group, preferably as an ester, e.g., with a lower alkyl, benzyl or trimethylsilyl group. The protected carboxylic acid compound is coupled to an N-protected amino acid, e.g., glycine or L-alanine, protected on nitrogen with t-butyloxycarbonyl or benzyloxycarbonyl. The coupling is carried out by any of a variety of standard peptide coupling techniques as disclosed, for example, in "The Peptides. Analysis, Synthesis, Biology, Vol. 1 Major Methods of Peptide Bond Formation, Part A", ed.
E. Gross, J. Meierhofer, Academic Press N.Y. (1979). An especially useful method involves the use of a dehydrating agent, such as dicyclohexylcarbodiimide alone or in the presence of reagents forming reactive esters, e.g., l-hydroxy-benztriazole, in suitable aprotic solvents such as dimethylformamide, acetonitrile, tetrahydrofuran or chlorinated hydrocarbons. This gives the intermediate (N protected-2-aminoacyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid esters. These may then be either partially or totally deblocked depending on the protecting groups chosen, using anhydrous acids, e.g., hydrochloric acid in acetic acid or trifluoroacetic acid in methylene chloride, JJ:rn ,~

1331~ ~

or hydrogen gas and a catalyst to give the intermediate dipeptide either in free form or protected as an ester.
The compounds of the invention of formula I may then be prepared by reacting the intermediate dipeptide or its ester derivative with ~-keto-4-substituted phenylbutyric acid or its lower alkyl ester derivatives under dehydrating and reducing conditions. Preferred dehydrating agents include molecular sieves in aprotic solvents and preferred reducing agents include sodium cyanoborohydride or hydrogen gas with a catalyst.
Alternatively, the dipeptide or its ester derivative may be reacted with an ~-halo-4-substituted phenylbutyric acid or its ester in the presence of a suitable basic reagent, such as triethylamine or alkali carbonates or bicarbonates, in a solvent, to give the compounds of the invention of formula I. Ester protected products may be hydrolyzed under basic or acidic reaction conditions to free acid derivatives, or, in the case of benzyl esters, catalytic hydrogenolysis may be preferred.
Alternately, compounds of the invention of formula I may be prepared in a differe~t manner. This consists of applying either of the two methods described above for the attachment of the 2-(4-phenylbutyric acid) moiety to the protected dipeptide, first to glycine or L-alanine, which may be protected as an ester, to give N-[2-(4-phenylbutyric acid)]-substituted glycine or L-alanine derivative.
After selective deblocking of the acid moiety on the glycine or alanine portion of the product, the resulting monoacid may be coupled, either directly or subsequent to suitable blocking of the amino group, via standard peptide coupling procedures to the 1,2,3,4-tetrahydro-3-isoquinoline carboxylate, protected as an ester. Selective or complete removal of the ester groups and any amine protecting groups yield the compounds of formula I.
The products are obtained typically as a mixture of diastereoisomers which can be separated by standard methods of fractional crystallization or chromatography.

JJ:rn r., `.
b~

-` 133~

The compounds of this invention form acid salts with various inorganic and organic acids which are also within the scope of the invention. The pharmaceutically acceptable acid adclition salts of the compounds of the present invention may be prepared by conventional reactions by reacting the free amino acid or amino ester form of the product with one or more equivalents of the appropriate acid providing the desired anion in a solvent or medium in which the salt is insoluble, or in water and removing the water by freeze drying. The salts of strong acids are preferred. As exemplary, but not limiting, of pharmaceutically a~ceptable acid salts are the salts of hydrochloric, hydrobromic, sulfuric, nitric, acetic, fumeric, malic, maleic and citric acids.
The action of the enzyme renin on angiotensinogen, a pseudoglobuline in blood plasma, produces the decapeptide angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to the octapeptide angiotensin II.
The latter is an active pressor substance which has been implicated as the causative agent in various forms of hypertension in various mammalian species, e.g., rats and dogs. The compounds of this invention intervene in the renin->angiotensin I->angiotensin II sequence by inhibiting angiotensin I converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II, and therefore are useful in reducing or relieving hypertension.
Thus by the administration of a composition containing one or a combination of compounds of formula I or pharmaceutically acceptable salts thereof, hypertension in the species of mammal suffering therefrom is alleviated. A
single dos`e, or preferably two to four divided daily doses, provided on a basis of about 0.1 to 100 mg per kilogram per day, preferably about 1 to 50 mg per kilogram per day, is appropriate to reduce blood pressure. The substance is preferably administered orally, but parenteral routes such as subcutaneously, intramuscularly, intravenously or intraperitonealy can also be employed.

JJ:rn ~33~

In vitro ACE Assay: Angiotensin converting enzyme (ACE) inhibitory activity was determined by assaying guinea pig serum ACE in the presence and absence of the test compound. ACE from guinea pig serum and the test compounds were preincubated for 10 minutes before the addition of the labelled substrate 3H-hippuryl-qlycyl-glycine. After a 60 minute incubation of 37C the reaction was stopped by the addition of O.lN HCl. ACE cleaves the hippuryl-glycyl bond to form the dipeptide glycyl-glycine and 3H-hippuric acid.
The 3H-hippuric acid was then extracted with ethyl acetate and the ACE of a given sample calculated as the amount of 3H-hippuric acid generated.

JJ:rn s~
' . , 1 3 3~

TAELE

Acyl Derivatives of 1,2,3,4-Tetrahydrdoisoquinoline-3-carboxylic Acids (S,S,S configuration) and their In-Vitro 5Angiotensin-Converting Enzyme Inhibitory Activity COOR
CH O l*
/==\ * ~ 3 ~ "~

COOR2 ~3~ X
Y

.. __IL .. ~ = ---- r-- . _ . __._ R R2 X YOptical RotationACE I Activity l t'Y]D23 (in vitro) ¦ ::
._ ._ . ICso Molat Conc.
H Et H H+10.9 (1.0% EtOH)t 8.3 x 10-9 H EtOCH3OCH3+31.6~ (1.0% EtOH)t5.6 x 10-9 H H H H+14.5 (l.0æ MeOH)t 2.8 x 10-9 l - ~:
.. _ . .... 11 H _ H OCH3OCH3+37.8 (1.0% MeOH)t3.4 x 10-9 PhCH2 Et H H-11.7 (1.0% MeOH)# 2.0 x 10 t-Bu Et H H+ 6.4 (2.09~ MeOH)#3.2 x 10~ l .__ .. _ 11 PhCH2 EtOCH3 OCH3+ 3.4 (1.0% EtOH)#3.0 x 10-7 ! ~
t Hydtochlotide Salt # Maleate Salt ~ .
~ JJ:rn b,~

1333L~1~

The compounds of the invention can be utilized to achieve the reduction of blood pressure by formulating in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. About lo to 500 mg of a compound or mixture of compounds of formula I or II or ph~siologically acceptable salt thereof is compounded with a physiologically acceptable vehicle, carrier, excipient binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl par;abens as~preservatives, a dye and a flavoring such as cherry or orange flavor.
Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a synthetic fatty JJ:rn j: :' , . . : i :

133~

vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required~
The invention is illustrated by the following 5 examples.

EXAMP~E 1 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino~
oxopropyl]-1 2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Hydrochloride. Hydrate 10 (S.S.S), A quantity of 0.0079 mole of the hydrochloride of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,~,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester (S,S,S) 15 dissolved in 100 ml of tetrahydrofuran was catalytically debenzylated with hydrogen and 0.5 g of 2096 Pd/carbon at low pressure. The catalyst was filtered off and the product was precipitated as a relatively nonhydroxopic solid by the addition of a 10 fold quantity of ether; wt 3.7 g (88~6); mp 120-140C; tlc (20% MeOH-CHCl3/SiO2) one spot, Rf 0-5--0-7; [~]D23 = + 31.6 (1.05% EtOH).
Anal- Calc'd for C27H34N27 HCl H2 C, 58.63; H, 6.74; N, 5.07 Found: C, 58.59; H, 6.38; N, 5.06 The noncrystalline diester hydrochloride starting material used above was prepared by treatment of 5.54 g (0.0079 mole) of the maleate salt (prepared by the process of Example 5) with excess saturated sodium bicarbonate, extraction of the free base into 50% ether-ethyl acetate, treatment of this solution with excess hydrogen chloride and concentration at reduced pressure.

JJ:rn .: - :. . , ... : . .,., ., ~: ~. . ..

1331~

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1 2.3,4-tetrahydro-3-isoquinolinecarboxylic A~d, Hydrochloride Hydrate (S S S).
5 Procedure A: Debenzylation procedure.
2-[2-[tl-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1~2,3~4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate, (S,S,S) (prepared by the procedure of Example 6) was catalytically debenzylated 10 by the procedure set forth in Example 1 to yield the product; mp 105-120C; yield, 56%; tlc (20% MeOH-CHC13/
Sio2) one spot Rf 0.5-0.6; [~x]D23 = ~10.9 (1.03g~ EtOH).
Anal. Calc'd for C25H30N2O5-HCl-H2O:
C, 60.90; H, 6.75; N, 5.68 Found: C, 61.00; H, 6.37; N, 5.59 Procedure B: Via cleavage of 1,1-dimethylethyl ester.
A quantity of 100 g of trifluoroacetic acid was added to 11.6 g (0.023 mole) of 2-[2-[~1-ethoxycarbonyl)-3-phenylpropyl]amino]-l-oxopropyl]-l~2~3~4-tetrahydro-3 20 isoquinolinecarboxylic acid, 1,1-dimethylethyl ester (S,S,S) (prepared by the procedure of Example 7). The mixtur~ was stirred to solution and for one hour at room temperature. Most of the trifluoroacetic acid was removed on the rotary evaporator and the remaining traces were 25 removed by the successive additions and removal by rotary evaporation of 2 x 50 ml of THF. The residual oil was dissolved in about 400 ml of dry ether and the hydrochloride was precipitated by addition of a solution of 1.0 g (excess) of dry hydrogen chloride dissolved in 20 30 ml of dry ether. After filtration and washing with dry ether, the filter cake was dissolved in about 250 ml of water. This solution was filtered through celite and freeze-dried to obtain the product as a partial hydrate;
10.0 g (90%); mp 113-120C.
35 Anal. Calc'd for C25H30N2O5-HCl-3/4 H2O:
C, 61.55; H, 6.70; N, 5.74 Found: C, 61.51; H, 6.49; N, 5.70 j~ JJ:rn `: `::`:: ` . ~ ' ` ': ` .

1 3 3 ~

2-[2- r ( 1-Carboxy-3-~henylpropvl)aminol-1-oxo~ropvl]-1 2.3,4-tetrahYdro-6,7-dimethoxy-3-isoquinolinecarboxylic ~aid, Hydrochloride~ Hydrate (S,S S).
A solution of 0.553 g ~0.001 mole) of 2-[2-[[1-~ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) (prepared by the process of Example 1) in 4 ml (0.004 mole) of lN sodium hydroxide and 4 ml of methanol was allowed to stand at room temperature for 20 hollrs. The reaction solution was added to 5 ml of lN hydrochloric acid and concentrated at reduced pressure. The last amounts of water were removed by two successive additions and removal at reduced pressure of 25 ml portions of ethanol. The organic portion of the residue was dissolved in 0.5 ml of methanol. Chloroform ~30 ml) was added and the solution was dried over sodium sulfate, charcoaled, filtered, and concentrated to give 0.45 g product. This amorphous material was dissolved in 20 ml of tetrahydrofuran and 100 ml of ether was added to precipitate a near white solid product; wt 0.4 g; mp 145-170C; yield, 80%; tlc (20%
MeOH-CHC13/Si02) Rf 0.1; [~]D23 = +37.8 (1.09% MeOH).
Anal. Calc'd for C25H30N2O7 HCl H2O:
C, 57.19; H, 6.34; N, 5.34 Found: C, 57.17; H, 6.10; N, 5.51 EXaNPLE 4 2-~2-~(1-Carboxy-3-phenylpropyl)amino~-1-oxopropyl~-1,2 3,4-tetrahydro-3-isoquinolinecarboxylic Acid Hydrochloride, Hemihydrate (S S,S).
2-[2-~[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) was treated by the procedure set forth in Example 3 to yield the product; mp 140-170C; yield, 39%; [~]D23 = +14.5 (1.08% MeOH).
Anal. Calc'd for C23H26N2O5 HCl-l/2 H2O:

JJ:rn .

1 3 3 ~

C, 60.59; H, 5.97; N, 6.15; Cl, 7.77 Found: C, 60.68; H, 6.04; N, 5.89; Cl, 7.04 EXAMPLE S
2-~2- r r 1- ( Ethoxycarbonyl)-3-phenylpro~yllamino]-1-oxo~ropyl]-1,2.3.4-tetrahydro-6,7-dimethoxy-3-i~oquinolinecarboxylic Acid Phenylmethyl Ester, Maleate (S,S,S) .
A stirred solution of 5.0 g (0~0158 mole) of ethyl ~-[(1-carboxyethyl)amino]benzenebutanoate hydrochloride (S,S) (prepared by the process of Example 8) in 200 ml of methylene chloride was treated successively with 1.60 g (0.0158 mole) of triethylamine, 2.14 g (0.0158 mole) of 1-hydroxybenzotriazole, 5.16 g (0.0158 mole) of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic acid, phenylmethyl ester free base (S-form) (prepared by the process of Example 9); and then with 3.26 g (0.0158 mole) of dicyclohexylcarbodiimide in 10 ml of methylene dichloride. Dicyclohexylurea gradually separated. The mixture was allowed to stand at room temperature overnight. Hexane (300 ml~ was added and the urea was filtered. The filtrate was washed with 250 ml of saturated sodium bicarbonate, dried over sodium sulfate and concentrated to remove solvent. The viscous residue was triturated with 50 ml of ether and filtered to remove insolubles. The filtrate was concentrated to give 9.2 g (99~) of crude base.
Preparation of maleate salt: A solution of 9.0 g (0.015 mole) of the above crude base in 50 ml of ethyl acetate was treated with a warm (40C) solution of 1.86 g (0.016 mole) of maielc acid in 50 ml of ethyl acetate.
White crystals separated; wt 7.2 g (65%); mp 139-141C;
tlc of base (generated with aq. sodium bicarbonate treatment of the salt and ethyl acetate extraction) showed one spot, Rf 0.7 (EtoAc/Sio2). Recrystallization from ethyl acetate gave pure material of the same mp; ~]D23 =
+3.4 (1.05% EtOH).

JJ:rn ~33~

Anal. Calc'd for C34H40N207-C4H404 C, 64.74; H, 6.29; N, 3.98 Found: C, 64.48; H, 6.30; N, 3.99 EX~MPLE 6 2- r 2-[[1-(Ethoxycarbonyl)-3-~henyl~ropvl1amino1-1-oxopropyl]-1,2.3.4-tetrahydro-3-isoquinolinecarboxylic Acid, Phenylmethyl Ester, Maleate (S.S.S).
Ethyl ~-[(1-carboxyethyl)amino]benzenebutanoate hydrochloride (S,S) (prepared by the process of Example 8) was coupled with 1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, phenylmethyl ester free base (S-form) (prepared by the process of Example 10) by the same procedure used in Example 5; yield, 61%; mp 151-153C
(recrystallized from ethyl acetate); tlc of base showed one spot, Rf 0.8 (EtoAC/Sio2); [~]D23 = -11.7 ~1.0% MeOH).
Anal. Calc'd for C32H36N2Os-C4H4o4:
C, 67.07; H, 6.25; N, 4.35 Found: C, 66.58; H, 6.09; N, 4.25 EXAMP~E 7 2-t2-~1-Ethoxycarbonyl)-3-phenylpropyl~aminol-1-oxop~Qpyl]-1.2.3.4-tetrahydro-3-isoquinolinecarboxylic Acid. 1.1-Dimethylethyl Ester (S.S.S).
A mixture of 8.38 g (0.03 mole) of ethyl ~-[(1-carboxyethyl)amino]benzenebutanoate (free amino acid) (S,S) (prepared by the process of Example 8), 8.09 g (0.03 mole) of 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, l,1-dimethylethyl ester hydrochloride (S-form) (prepared by the process of Example 11), 4.05 g (0.03 mole) of 1-hydroxybenzotriazole and 250 ml of THF was cooled in an ice bath to 3-5C. With stirring, 3.04 g (0.03 mole) of triethylamine was added, then a solution of 6.92 g ~0.0335 mole) of dicyclohexylcarbodiimide in 30 ml of THF was dropped in slowly over 20 minutes. The reaction mixture was stirred at 3-5C for one hour. The ice bath was removed, and the reaction mixture stirred an additional 3 JJ:rn 1~3~$~ ~

hours. The separated mixture of triethylamine hydrochloride and dicyclohexylurea was removed by filtration and washed with THF. The filtrate was evaporated on the rotary evaporation to remove all volatiles. The resulting gum was dissolved in about 300 ml of ethyl acetate. After filtration through celite the ethyl acetate solution was extracted 2 times with 100 ml of saturated sodium bicarbonate solution, once with 75 ml of 2N citric acid solution, once with 100 ml of saturated sodium bicarbonate solution and once with 100 ml of saturated sodium chloride solution. After drying with anhydrous MgSO4 and filtration, the ethyl acetate was removed on the rotary evaporator to yield 16.9 g of a light brown gum. This gum was dissolved in 350 ml of boiling hexane and decanted through celite. The hexane solution was cooled in ice, seeded and stirred until crystallization was well established. The product was filtered, washed with cold hexane and dried; wt 11.6 g (78%); mp 68.5-71C; [~]D = -12.2 (2% MeOH). Pure material had mp 71-72C; [~]D23 = -12.6 (2% MeOH). The maleate salt had mp 127.5-128.5C; [a]D23 = +46.4 (2%
MeOH).

Ethyl ~L(l-Carboxyethyl)amino]benzenebutanoate Hydrochloride ~S.S).
A solution of 2.0 g of t-butyl alanine (S-form) and 3.78 g of ethyl 2-bromo-4-phenylbutanoate in 25 ml of dimethylformamide was treated with 1.8 ml of triethylamine and the solution was heated at 70C for 18 hours. The solvent was removed at reduced pressure and the residue was mixed with water and extracted with ethyl ether. The organic layer was washed with water and dried over magnesium sulfate. Concentration of the solvent at reduced pressure gave the oily t-butyl ester of the intermediate which was found to be sufficiently pure by gas liquid chromatography for further use.

JJ:rn 1331~1~

A solution of 143.7 g of this t-butyl ester in 630 ml of trifluoroacetic acid was stirred at room temperature for one hour. The solvent was removed at reduced pressure and the residue was dissolved in ethyl ether and again evaporated. This operation was repeated. Then the ether solution was treated dropwise with a solution of hydrogen chloride gas in ethyl ether until precipitation ceased.
The solid, collected by filtration, was a mixture of diastereoisomers, mp 153-165C, [~D~ = +3.6 ~1% MeOH).
In order to separate the preferred S, S isomer, a suspension of 10.0 g of the mixture in 200 ml of methylene chloride was stirred at room temperature for five minutes and filtered; the solid was washed with additional methylene chloride and finally ether. The solid material, mp 202-208C (dec.), [~]D23 = -29.3 (1% MeOH) was the less preferred diastereoisomer having the R, S configuration (Si referring to the portion derived form L-alanine). The preferred S, S diastereoisomer was recovered from the filtrate after concentration and trituration of the residue with ether; mp 137-139C; t~]D23 = +31.3 (1%
MeOH).
The free amino acid (S,S-form) was prepared by treatment of an aqueous solution of the hydrochloride with saturated sodium acetate. The product was filtered, washed efficiently with cold water and recrystallized from ethyl acetate; mp 149-151C; [~]D~ = +29.7 (1~ 0.1N HCl).

1.2 3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Phenylmethyl Ester! Hydrochloride (S-form).
A mixture of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride (S-form) and 600 ml of benzyl alcohol was saturated with hydrogen chloride gas. The temperature rose to 45C. The mixture was stirred at room temperature for three days. A
relatively small amount of solid was filtered off and the filtrate was treated with ca 2-liters of ether to JJ:rn ST,.

, 133~

precipitate crude product; wt 37.5 g; yield, 83%.
Purification was effected by treatment with excess saturated sodium bicarbonate, extraction of base into ethyl acetate and precipitation of hydrochloride salt with HCl gas. Recrystallization from methanol-ether gave pure product; mp 255-260; [a]D23 = -81.3 (1.0% MeOH); tlc (20%
MeOH-CHC13/SiO2) one spot Rf 0.8.
Anal. Calc'd for Cl9H2lN04-HCl:
C, 62.72; H, 6.10; N, 3.85 Found: C, 62.54; H, 5.99; ~, 4.00 EXAMP~E 10 1.2 3,4-Tetrahydro-3-isoquinolinecarboxylic Acid Phenylmethyl Ester Hydrochloride (S-form).
Benzyl alcohol, 750 ml, was treated with 150 g of commercial polyphosphoric acid and warmed and stirred at 90C to obtain a homogeneous mixture. Solid 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (S-form) 165.2 g was added. The mixture was stirred 4 hours at 95-105C
and then allowed to stand at room temperature for 18 hours. A solution of 18.5 g gaseous hydrochloric acid in 2.5 l of anhydrous ether was added, and the produat separated slowly on cooling overnight. Filtration gave the crude benzyl 1,2,3,4-tetrahydro-3-isoquinoline carboxylate hydrochloride. This was purified by recrystallization from ethanol twice to give material with mp 190.5-191C; [~]D~ = -83.3 (1% 1:1 methonal/lN
hydrochloric acid).

1.2.3.4-Tetrahydro-3-isoquinolinecarboxylic Acid. 1~1-Dimethylethyl Ester Hydrochloride (S-form).
This compound was prepared by passing 447 g of isobutylene into a 0C solution of 63.5 g of 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (S-form) in 650 ml of dry dioxane and 65 ml of concentrated sulfuric acid under nitrogen. The reaction vessel was sealed and shaken `

JJ:rn 1331~15 for 17 hours at room temperature. The reaction vessel was vented and the mixture was poured into 25 l of cold 2N
sodium hydroxide. The product is extracted into ether.
The ether solution was washed with water, dried, and concentrated to about 500 ml. This was treated with excess 6N isopropanolic hydrochloric acid to precipitate the product, which was collected by filtration. A sample purified by recrystallization from ethanol/ether had mp 190-192C (dec.), [~]D~ = -88.7 (2~ MeOH).

A quantity of 1000 tablets each containing 100 mg of 2-E2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) is produced from the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-l-oxopropyl]1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride hydrate (S,S,S) 100 g Corn starch 50 g Gelatin 7.5 g Avicel (microcrystalline cellulose) 25 g Magnesium stearate 2.5 g 2-~2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) and corn starch are admixed with an aqueous solution of the gelatin. The mixture is dried and ground to fine powder. The Avicel and then the magnesium stearate are admixed with the granulation. This is then compressed in a tablet press to form 1000 tablets each containing lOO mg of active ingredients.

JJ:rn .::

1331~ ~

A quantity of 1000 tablets each containing 200 mg of 2-t2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) is produced from the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-l-oxopropyl]-1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride hydrate (S,S,S) 200 g Lactose 100 g Avicel 150 g Corn starch 50 g Magnesium stearate 5 g The 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]
amino]-l-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) lactose and Avicel are admixed, then blended with the corn starch. Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000, 505 mg tablets each containing 200 mg of active ingredient.
The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake containing yellow No. 6.

Two piece No. 1 gelatin capsules each containing 250 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) are filled with a mixture of the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-l-oxopropyl]-1,2,3,4-Tetrahydro-6,7-JJ:rn 1331~1~

dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) 250 mg Magnesium stearate 7 mg USP lactose 193 mg An injectable solution is produced as follows:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-1-oxopropyl~-1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) 500 g Methyl paraben 5 g Propyl paraben 1 g Sodium chloride 25 g Water for injection q.s. 5 1 , The active substance, preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume i8 brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are then closed with presterilized rubber closures. Each vial contains 5 ml of solution in a concentration of 100 mg of active ingredient per ml of solution for injection.

JJ:rn .. , ... . . . - .. ..

Claims (5)

1. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinone-3-carboxylic acid in the form of the (S,S,S) isomer having the following general formula:

(I) where R2 is a hydrogen atom or an ethyl radical, in one of the following acid salt forms: the hydrochloride, hydrate; the hydrochloride; and the hydrochloride hemihydrate.
2. 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, benzyl ester, maleate (S,S,S).
3. 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester (S,S,S).
4. 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).
5. 2-[2-[(1-Carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hemihydrate (S,S,S).
CA000616412A 1980-10-03 1992-06-23 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids Expired - Lifetime CA1331615C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000616412A CA1331615C (en) 1980-10-03 1992-06-23 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19376780A 1980-10-03 1980-10-03
US193,767 1980-10-03
US06/236,397 US4344949A (en) 1980-10-03 1981-02-20 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US236,397 1981-02-20
CA000387002A CA1341330C (en) 1980-10-03 1981-09-30 Substituted acyl dertivatives of 1,2,3,4-tetrahydroisquinoline-3-carboxylic acids
CA000616412A CA1331615C (en) 1980-10-03 1992-06-23 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA000387002A Division CA1341330C (en) 1980-10-03 1981-09-30 Substituted acyl dertivatives of 1,2,3,4-tetrahydroisquinoline-3-carboxylic acids

Publications (1)

Publication Number Publication Date
CA1331615C true CA1331615C (en) 1994-08-23

Family

ID=26889329

Family Applications (3)

Application Number Title Priority Date Filing Date
CA000387002A Expired - Lifetime CA1341330C (en) 1980-10-03 1981-09-30 Substituted acyl dertivatives of 1,2,3,4-tetrahydroisquinoline-3-carboxylic acids
CA000616411A Expired - Lifetime CA1331614C (en) 1980-10-03 1992-06-23 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline- 3-carboxylic acids
CA000616412A Expired - Lifetime CA1331615C (en) 1980-10-03 1992-06-23 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA000387002A Expired - Lifetime CA1341330C (en) 1980-10-03 1981-09-30 Substituted acyl dertivatives of 1,2,3,4-tetrahydroisquinoline-3-carboxylic acids
CA000616411A Expired - Lifetime CA1331614C (en) 1980-10-03 1992-06-23 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline- 3-carboxylic acids

Country Status (23)

Country Link
US (1) US4344949A (en)
EP (2) EP0096157B1 (en)
JP (1) JPS5788164A (en)
KR (1) KR880001326B1 (en)
AT (2) ATE25974T1 (en)
AU (2) AU551239B2 (en)
CA (3) CA1341330C (en)
DD (1) DD201787A5 (en)
DE (3) DE19575041I2 (en)
DK (1) DK163120C (en)
ES (1) ES8301925A1 (en)
FI (2) FI78690C (en)
GR (1) GR75353B (en)
HK (1) HK43389A (en)
IE (2) IE52666B1 (en)
IL (1) IL63806A (en)
LU (1) LU88321I2 (en)
MX (1) MX155144A (en)
MY (1) MY100440A (en)
NL (2) NL930077I2 (en)
NO (1) NO159017C (en)
PH (1) PH17740A (en)
SG (1) SG15689G (en)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460775A (en) * 1979-08-09 1984-07-17 Norwich Eaton Pharmaceuticals, Inc. 2-(3-Mercapto-1-oxopropyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid derivatives
US4595675A (en) * 1979-09-19 1986-06-17 Hoechst Aktiengesellschaft Bicyclic α-iminocarboxylic acid compounds having hypotensive activity
US4565819A (en) * 1979-12-07 1986-01-21 Adir Substituted imino diacids, their preparation and pharmaceutical compositions which contain them
FR2503155A2 (en) * 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4616030A (en) * 1979-12-07 1986-10-07 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4616029A (en) * 1979-12-07 1986-10-07 Adir Perhydromdole-2-carboxylic acids as antihypertensives
US4644008A (en) * 1979-12-07 1987-02-17 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4616031A (en) * 1979-12-07 1986-10-07 Adir Perhydroindole-2-carboxylic acids as antihypertensives
EP0046953B1 (en) * 1980-08-30 1989-12-06 Hoechst Aktiengesellschaft Amino acid derivatives, processes for their preparation, compositions containing them and their use
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4532342A (en) * 1981-02-20 1985-07-30 Warner-Lambert Company N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
IN156096B (en) * 1981-03-19 1985-05-11 Usv Pharma Corp
EP0065301A1 (en) * 1981-05-18 1982-11-24 Merck & Co. Inc. Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same
DE3134933A1 (en) * 1981-09-03 1983-03-31 Hoechst Ag, 6230 Frankfurt "UREA DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE MEDICINES THEREOF AND THE USE THEREOF"
DE3226768A1 (en) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
EP0081094A1 (en) * 1981-11-12 1983-06-15 Merck & Co. Inc. Substituted omega-amino-carboxymethyldipeptide antihypertensive agents
CA1341296C (en) * 1981-12-29 2001-09-25 Hansjorg Urbach 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use
IE54551B1 (en) * 1982-01-22 1989-11-22 Ici Plc Amide derivatives
US4665087A (en) * 1982-02-22 1987-05-12 Ciba-Geigy Corporation 1-(carbamyl, thiocarbamyl, and iminocarbamyl)-indoline derivatives
US4483850A (en) * 1982-05-10 1984-11-20 Merck & Co., Inc. N-Terminal substituted oligopeptide converting enzyme inhibitors
US4617291A (en) * 1982-05-14 1986-10-14 Mead Johnson & Company Angiotensin-converting enzyme inhibiting dipeptide derivatives
US4427665A (en) 1982-05-19 1984-01-24 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions
EP0099709A3 (en) * 1982-07-19 1985-11-13 Imperial Chemical Industries Plc Amide derivatives
US4500713A (en) * 1982-09-23 1985-02-19 Usv Pharmaceutical Corporation Therapeutic dipeptides
DE3302125A1 (en) * 1983-01-22 1984-07-26 Boehringer Ingelheim KG, 6507 Ingelheim AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
US4659711A (en) * 1983-01-31 1987-04-21 Usv Pharmaceutical Corporation 1,2,3,4-Tetrahydrophthalazine and hexahydropyridazine compounds for treating hypertension
DE3303344A1 (en) 1983-02-02 1984-08-02 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED AMINO ACIDS AND THEIR ESTERS
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3333455A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS
DE3333454A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS
US4542234A (en) * 1983-10-06 1985-09-17 Usv Pharmaceutical Corp. Process for the separation of (S,S) diastereoisomers
DE3345355A1 (en) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt METHOD FOR RACEMATE CLEAVING BICYCLIC IMINO (ALPHA) CARBONIC ACID ESTERS
DE3413710A1 (en) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt METHOD FOR TREATING HEART INSUFFICIENCY
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
US4584299A (en) * 1984-05-21 1986-04-22 Warner-Lambert Company Method of treating heart failure and medicaments therefor
GB8422165D0 (en) * 1984-09-01 1984-10-03 Wellcome Found Compounds
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4785089A (en) * 1985-06-13 1988-11-15 Ciba-Geigy Corporation Novel sulfonic acid esters and their preparation
US4652668A (en) * 1985-07-03 1987-03-24 Biomeasure, Inc. Aromatic amino acid derivatives
DE3529960A1 (en) * 1985-08-22 1987-03-05 Boehringer Ingelheim Kg AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
EP0254032A3 (en) 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0566157A1 (en) 1986-06-20 1993-10-20 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
JP2535001B2 (en) * 1987-01-13 1996-09-18 ダイセル化学工業株式会社 Process for producing N-alkylated amino acid ester
US5262436A (en) * 1987-03-27 1993-11-16 Schering Corporation Acylamino acid antihypertensives in the treatment of congestive heart failure
US4761479A (en) * 1987-03-30 1988-08-02 Warner-Lambert Company Crystalline quinapril and a process for producing the same
FR2620699B1 (en) * 1987-09-17 1990-06-01 Adir PROCESS FOR THE SYNTHESIS OF ALPHA AMINO N ALKYL ACIDS AND THEIR ESTERS. APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES
FR2620700B1 (en) * 1987-09-17 1990-06-01 Adir PROCESS FOR THE SYNTHESIS OF ALPHA AMINO ACIDS N ALKYLS AND THEIR ESTERS. APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES
DE3739690A1 (en) * 1987-11-24 1989-06-08 Hoechst Ag STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS
US5055588A (en) * 1988-07-06 1991-10-08 Daicel Chemical Industries Ltd. Process for preparing N-substituted amino acid esters
US4912221A (en) * 1988-10-27 1990-03-27 Occidental Chemical Corporation Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof
DD284030A5 (en) 1988-11-24 1990-10-31 Hoechst Ag,De PROCESS FOR THE PREPARATION OF PEPTIDES WITH BRADYKININ-ANTAGONISTIC EFFECT
ZA902661B (en) * 1989-04-10 1991-01-30 Schering Corp Mercapto-acyl amino acids
WO1991007386A1 (en) * 1989-11-21 1991-05-30 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
AU7168091A (en) * 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
US5173506A (en) * 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
TW197945B (en) * 1990-11-27 1993-01-11 Hoechst Ag
TW258739B (en) * 1992-04-04 1995-10-01 Hoechst Ag
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
GB2266529A (en) * 1992-05-01 1993-11-03 Merck Sharp & Dohme Tetrahydroisoquinoline derivatives
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
EP0739898B1 (en) * 1995-03-13 2001-09-26 Aventis Pharma Deutschland GmbH Phosphonomonoester nucleic acids, methods for their preparation and their use
PT796855E (en) 1996-03-20 2002-07-31 Hoechst Ag INHIBITION OF REABSORCAO IN BONES AND ANTAGONISTS OF VITRONECTIN
FR2746394B1 (en) 1996-03-20 1998-05-29 Roussel Uclaf NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS, AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE19612067A1 (en) * 1996-03-27 1997-10-02 Hoechst Ag Use of bradykinin antagonists for the manufacture of medicaments for the treatment of chronic fibrogenetic liver diseases and acute liver diseases
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
ES2122941B1 (en) * 1997-05-29 1999-07-01 Esteve Quimica Sa PROCEDURE FOR OBTAINING QUINAPRIL CHLORHYDRATE AND SOLVATES USEFUL FOR THE ISOLATION AND PURIFICATION OF QUINAPRIL CHLORHYDRATE.
DE19741235A1 (en) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
DE19751251A1 (en) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
ES2242398T3 (en) * 1998-06-05 2005-11-01 Warner-Lambert Company Llc STABILIZATION OF COMPOSITIONS CONTAINING INHIBITORS OF THE ANGIOTENSIN CONVERSION ENZYME USING MAGNESIUM OXIDE.
WO2000002862A1 (en) 1998-07-08 2000-01-20 G.D. Searle & Co. Retroviral protease inhibitors
US6191144B1 (en) 1998-08-17 2001-02-20 Warner-Lambert Company Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
IL146000A0 (en) * 1999-04-30 2002-07-25 Millennium Pharm Inc Ace-2 inhibiting compounds and methods of use thereof
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
EP1267914B2 (en) 2000-02-04 2013-11-06 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
CA2303481A1 (en) * 2000-04-05 2001-10-05 Bernard Charles Sherman Pharmaceutical compositions comprising moexipril magnesium
FR2807430B1 (en) * 2000-04-11 2002-05-17 Adir NOVEL PROCESS FOR THE SYNTHESIS OF N - [(S) -1- CARBOXYBUTYL] - (S) -ALANINE ESTERS AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL
US8101363B2 (en) 2000-12-14 2012-01-24 The Brigham And Women's Hospital, Inc. Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
JP2005503378A (en) * 2001-08-06 2005-02-03 ジエノメツド・エル・エル・シー Methods and compositions for treating diseases associated with ACE excess
WO2003043624A1 (en) * 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
SI2336359T1 (en) 2002-05-09 2016-08-31 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker
CA2388475C (en) 2002-05-31 2009-12-08 Brantford Chemicals Inc. Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040110241A1 (en) * 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
CA2510773C (en) * 2002-12-16 2010-04-13 Lupin Limited Crystalline form of quinapril hydrochloride and process for preparing the same
JP2006521287A (en) 2002-12-20 2006-09-21 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ High pressure compression for pharmaceutical formulations
CL2004000366A1 (en) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
CL2004000544A1 (en) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B USE OF A PHARMACEUTICAL COMBINATION, OF AN ALGOSTERONE RECEIVER ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR, USEFUL FOR THE TREATMENT AND PREVENTION OF A PATHOLOGICAL CONDITION RELATED TO HYPERTENSION, RENAL DYSFUNCTION, INSULINOPATI
CL2004000541A1 (en) * 2003-03-31 2005-02-04 Warner Lambert Co PROCEDURE FOR PREPARATION OF QUINAPRIL CHLORHYDRATE BY REACTION BETWEEN A 2,5-DIOXO-OXAZOLIDINE AND A TERBUTILIC ESTER OF AN ISOQUINOLINE TETRAHYDRA, USED AS AN ACTIVE PRINCIPLE TO TREAT HYGERTENSION AND CARDIAC INSUFFICIENCY
KR20110117731A (en) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 Substituted Pyrrole Derivatives and Their Uses as HMV-CO Inhibitors
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7491743B2 (en) 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
KR20080016527A (en) * 2005-01-31 2008-02-21 밀란 래보러토리즈, 인크. Pharmaceutical Compositions Containing Hydroxylated Nebivolol
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8080579B2 (en) * 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007069268A2 (en) * 2005-10-14 2007-06-21 Sun Pharmaceutical Industries Limited A process for the preparation of substantially pure 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP5412273B2 (en) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Peptide-peptidase inhibitors and uses thereof
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN101143846B (en) * 2006-09-12 2011-02-02 南京新港医药有限公司 Metal salt of quinaprilat
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
CA2684308A1 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CN102149710A (en) 2008-06-24 2011-08-10 百时美施贵宝公司 Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-Kappa B activity and use thereof
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP2013518618A (en) 2010-02-01 2013-05-23 ザ・ホスピタル・フォー・シック・チルドレン Remote ischemic conditioning to treat and prevent restenosis
SG10201502031XA (en) 2010-03-31 2015-05-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
TWI621420B (en) 2010-04-08 2018-04-21 病童醫院 Use of remote ischemic conditioning for traumatic injury
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
RU2570752C2 (en) 2011-08-26 2015-12-10 Вокхардт Лимитед Method of treating cardiovascular diseases
CA2873214C (en) 2012-05-11 2021-02-16 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
AU2013296803B2 (en) 2012-08-01 2018-03-08 Eric Ostertag Free flowing, frozen compositions comprising a therapeutic agent
JP2016514693A (en) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Hybrid necrotosis inhibitor
HK1220611A1 (en) 2013-03-15 2017-05-12 Bausch Health Ireland Limited Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102069473B1 (en) 2013-03-21 2020-01-22 유프락시아 파마수티컬스 유에스에이 엘엘씨 Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
KR101695582B1 (en) 2013-04-17 2017-01-13 화이자 인코포레이티드 N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
SI3004138T1 (en) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2014202659A1 (en) 2013-06-21 2014-12-24 Sanofi-Aventis Deutschland Gmbh Process for the preparation of amides of n-[1-(s)-(ethoxycarbonyl)-3-phenylpropyl]-l-alanine
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
TWI690521B (en) 2014-04-07 2020-04-11 美商同步製藥公司 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11351124B2 (en) 2015-10-27 2022-06-07 Eupraxia Pharmaceuticals Inc. Sustained release of formulations of local anesthetics
CN119060040A (en) 2019-01-18 2024-12-03 阿斯利康(瑞典)有限公司 PCSK9 inhibitors and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691169A (en) * 1970-09-03 1972-09-12 Neisler Lab Inc 2-(alkylthioalkyl)-1,2,3,4-tetrahydroisoquinolines
US3929830A (en) * 1972-08-28 1975-12-30 Velsicol Chemical Corp N-({60 -thiocyanoacetyl)indolines
US4125604A (en) * 1974-11-08 1978-11-14 Mitsubishi Chemical Industries Limited N2-Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
US4052511A (en) * 1976-02-13 1977-10-04 E. R. Squibb & Sons, Inc. Carboxyacylproline derivatives
US4091024A (en) * 1976-12-03 1978-05-23 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
US4116962A (en) * 1976-12-03 1978-09-26 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
US4129566A (en) * 1978-02-15 1978-12-12 E. R. Squibb & Sons, Inc. Derivatives of dehydrocyclicimino acids
DE2720966C2 (en) 1977-05-10 1991-09-26 Karl Deutsch Prüf- und Meßgerätebau, 5600 Wuppertal Ultrasonic transmitter
IT7851510A0 (en) 1977-10-28 1978-10-16 Sandoz Ag AMIDES OF CYCLIC AMINO ACIDS THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES
CA1120400A (en) 1977-12-27 1982-03-23 Zola P. Horovitz Method of treating hypertension and medicaments therefor
US4154935A (en) * 1978-02-21 1979-05-15 E. R. Squibb & Sons, Inc. Halogen substituted mercaptoacylamino acids
JPS5572169A (en) * 1978-11-27 1980-05-30 Tanabe Seiyaku Co Ltd Isoquinoline derivative and its preparation
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4461896A (en) 1979-02-07 1984-07-24 Norwich Eaton Pharmaceuticals, Inc. 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
EP0018104B1 (en) * 1979-03-26 1983-05-25 Takeda Chemical Industries, Ltd. Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension
US4294832A (en) * 1979-04-28 1981-10-13 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
GB2048863B (en) 1979-05-16 1983-06-15 Morton Norwich Products Inc Tetrahydroisoquinoline-3-carboxylic acids
US4303583A (en) * 1979-08-13 1981-12-01 American Home Products Corporation 1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones
FR2487829A2 (en) * 1979-12-07 1982-02-05 Science Union & Cie NOVEL SUBSTITUTED IMINO ACIDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
FR2503155A2 (en) * 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
US4251444A (en) * 1980-04-07 1981-02-17 American Home Products Corporation Thiazepino-[4,3-b]-isoquinoline-1,5-dione derivatives and precursors
EP0046953B1 (en) * 1980-08-30 1989-12-06 Hoechst Aktiengesellschaft Amino acid derivatives, processes for their preparation, compositions containing them and their use

Also Published As

Publication number Publication date
FI79839B (en) 1989-11-30
DK163120C (en) 1992-06-15
CA1341330C (en) 2002-01-01
EP0096157A3 (en) 1984-09-12
FI78690B (en) 1989-05-31
IE52665B1 (en) 1988-01-20
NL960012I2 (en) 1997-02-03
NO813359L (en) 1982-04-05
NO159017B (en) 1988-08-15
AU5299186A (en) 1986-07-17
ATE25974T1 (en) 1987-04-15
FI813033L (en) 1982-04-04
AU563683C (en) 2001-12-20
HK43389A (en) 1989-06-07
ATE26120T1 (en) 1987-04-15
AU563683B2 (en) 1987-07-16
AU7541681A (en) 1982-05-06
MX155144A (en) 1988-02-01
SG15689G (en) 1989-06-09
DK163120B (en) 1992-01-20
JPH0316359B2 (en) 1991-03-05
DE3176029D1 (en) 1987-04-30
EP0049605A1 (en) 1982-04-14
PH17740A (en) 1984-11-23
MY100440A (en) 1990-09-29
KR880001326B1 (en) 1988-07-25
CA1331614C (en) 1994-08-23
NL930077I2 (en) 1993-10-01
GR75353B (en) 1984-07-13
US4344949A (en) 1982-08-17
FI78690C (en) 1989-09-11
ES505960A0 (en) 1982-12-16
IE812097L (en) 1982-08-20
NL930077I1 (en) 1993-09-16
NO159017C (en) 1988-11-23
DK436081A (en) 1982-04-04
FI881985A0 (en) 1988-04-27
LU88321I2 (en) 1994-05-04
IE52666B1 (en) 1988-01-20
KR830007567A (en) 1983-10-21
IE811566L (en) 1982-01-11
DD201787A5 (en) 1983-08-10
FI881985A7 (en) 1988-04-27
NL960012I1 (en) 1996-10-01
IL63806A (en) 1985-02-28
ES8301925A1 (en) 1982-12-16
EP0096157A2 (en) 1983-12-21
AU551239B2 (en) 1986-04-24
DE19575041I2 (en) 2001-11-22
EP0096157B1 (en) 1987-03-25
FI79839C (en) 1990-03-12
EP0049605B1 (en) 1987-03-18
DE3176010D1 (en) 1987-04-23
JPS5788164A (en) 1982-06-01

Similar Documents

Publication Publication Date Title
CA1331615C (en) Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
EP0088341B1 (en) Substituted acyl derivative of octahydro-1h-indole-2-carboxylic acid
KR850001269B1 (en) Preparation of Amino Acid Derivatives
EP0012401B1 (en) Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them
CA1205476A (en) Substituted acyl derivatives of octahydro-1h-indole-2- carboxylic acids
US4425355A (en) Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4532342A (en) N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
EP0065301A1 (en) Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same
EP0058567B1 (en) Substituted acyl derivatives of octahydro-1h-isoindole-1-carboxylic acids and esters
US5453488A (en) Amino-substituted heterocycles as renin inhibitors
US4490386A (en) Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof
US4749698A (en) Antihypertensive derivatives
US4746676A (en) Carboxyalkyl dipeptide compounds
US4503043A (en) Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids
CA1313724C (en) Aminoacid derivatives as antihypertensives
NZ198542A (en) Acyl derivatives of 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid derivatives
EP0059966A1 (en) Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives
IE52664B1 (en) Substituted acyl derivative of octahydro-1h-indole-2-carboxylic acid
FI76560B (en) FOR EXAMINATION OF PHARMACEUTICAL PRODUCTS 1- / 2 - / (1-CARBETOXY-3-PHENYLPROPYL) AMINO / -1-OXOPROPYL / -OCTAHYDRO-1H-INDOL-2-CARBOXYL SYRA.
JPH01110695A (en) Amino acid derivative as hypotensive agent

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20110823